XOMA ROYALTY CORPORATION (XOMA) Stock Fundamental Analysis
USA - NASDAQ:XOMA - US98419J2069 - Common Stock
32.64 USD
+0.4 (+1.24%)
32.64 USD
0 (0%)
We assign a fundamental rating of 4 out of 10 to XOMA. XOMA was compared to 531 industry peers in the Biotechnology industry. XOMA has a medium profitability rating, but doesn't score so well on its financial health evaluation. XOMA is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year XOMA has reported negative net income.
XOMA had a negative operating cash flow in the past year.
In multiple years XOMA reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: XOMA reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of XOMA (-7.93%) is better than 85.12% of its industry peers.
Looking at the Return On Equity, with a value of -19.17%, XOMA belongs to the top of the industry, outperforming 84.18% of the companies in the same industry.
With an excellent Return On Invested Capital value of 3.73%, XOMA belongs to the best of the industry, outperforming 91.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.93% | ||
| ROE | -19.17% | ||
| ROIC | 3.73% |
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Operating Margin, with a value of 21.23%, XOMA belongs to the top of the industry, outperforming 95.10% of the companies in the same industry.
The Profit Margin and Gross Margin are not available for XOMA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.23% | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so XOMA is destroying value.
Compared to 1 year ago, XOMA has more shares outstanding
The number of shares outstanding for XOMA has been increased compared to 5 years ago.
XOMA has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -5.12, we must say that XOMA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of XOMA (-5.12) is worse than 60.26% of its industry peers.
A Debt/Equity ratio of 1.11 is on the high side and indicates that XOMA has dependencies on debt financing.
The Debt to Equity ratio of XOMA (1.11) is worse than 77.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.11 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.12 |
ROIC/WACC0.42
WACC8.87%
2.3 Liquidity
A Current Ratio of 4.88 indicates that XOMA has no problem at all paying its short term obligations.
XOMA's Current ratio of 4.88 is in line compared to the rest of the industry. XOMA outperforms 54.61% of its industry peers.
XOMA has a Quick Ratio of 4.88. This indicates that XOMA is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of XOMA (4.88) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.88 | ||
| Quick Ratio | 4.88 |
3. Growth
3.1 Past
XOMA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -38.74%.
XOMA shows a strong growth in Revenue. In the last year, the Revenue has grown by 168.71%.
The Revenue has been growing by 9.17% on average over the past years. This is quite good.
EPS 1Y (TTM)-38.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.62%
Revenue 1Y (TTM)168.71%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%18.39%
3.2 Future
XOMA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 37.32% yearly.
XOMA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 35.53% yearly.
EPS Next Y126.86%
EPS Next 2Y49.97%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue Next Year85%
Revenue Next 2Y45.1%
Revenue Next 3Y35.53%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for XOMA. In the last year negative earnings were reported.
XOMA is valuated quite expensively with a Price/Forward Earnings ratio of 63.59.
XOMA's Price/Forward Earnings ratio is rather cheap when compared to the industry. XOMA is cheaper than 88.51% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of XOMA to the average of the S&P500 Index (34.59), we can say XOMA is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 63.59 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of XOMA indicates a rather cheap valuation: XOMA is cheaper than 91.53% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 37.5 |
4.3 Compensation for Growth
XOMA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as XOMA's earnings are expected to grow with 37.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.97%
EPS Next 3Y37.32%
5. Dividend
5.1 Amount
No dividends for XOMA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
32.64
+0.4 (+1.24%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners68.05%
Inst Owner Change0.32%
Ins Owners1.4%
Ins Owner Change-11.59%
Market Cap394.62M
Revenue(TTM)44.95M
Net Income(TTM)-17.72M
Analysts82
Price Target71.06 (117.71%)
Short Float %2.15%
Short Ratio4.72
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.47
Dividend Growth(5Y)N/A
DP-30.88%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)207.59%
Min EPS beat(2)119.7%
Max EPS beat(2)295.48%
EPS beat(4)2
Avg EPS beat(4)28.19%
Min EPS beat(4)-256.98%
Max EPS beat(4)295.48%
EPS beat(8)3
Avg EPS beat(8)57.63%
EPS beat(12)4
Avg EPS beat(12)26.41%
EPS beat(16)5
Avg EPS beat(16)-3.83%
Revenue beat(2)2
Avg Revenue beat(2)76.76%
Min Revenue beat(2)32.7%
Max Revenue beat(2)120.82%
Revenue beat(4)3
Avg Revenue beat(4)39.95%
Min Revenue beat(4)-2.38%
Max Revenue beat(4)120.82%
Revenue beat(8)5
Avg Revenue beat(8)13.46%
Revenue beat(12)7
Avg Revenue beat(12)9.54%
Revenue beat(16)8
Avg Revenue beat(16)-1.84%
PT rev (1m)0%
PT rev (3m)7.73%
EPS NQ rev (1m)0%
EPS NQ rev (3m)72.73%
EPS NY rev (1m)0%
EPS NY rev (3m)371.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)8.53%
Revenue NY rev (1m)0%
Revenue NY rev (3m)10.53%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 63.59 | ||
| P/S | 8.78 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.27 | ||
| P/tB | 8.39 | ||
| EV/EBITDA | 37.5 |
EPS(TTM)-1.54
EYN/A
EPS(NY)0.51
Fwd EY1.57%
FCF(TTM)-1.91
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS3.72
BVpS7.65
TBVpS3.89
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.93% | ||
| ROE | -19.17% | ||
| ROCE | 4.73% | ||
| ROIC | 3.73% | ||
| ROICexc | 6.38% | ||
| ROICexgc | 10.37% | ||
| OM | 21.23% | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.2
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.11 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 9.33 | ||
| Cap/Depr | 1425.07% | ||
| Cap/Sales | 44.89% | ||
| Interest Coverage | 0.78 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.88 | ||
| Quick Ratio | 4.88 | ||
| Altman-Z | -5.12 |
F-Score5
WACC8.87%
ROIC/WACC0.42
Cap/Depr(3y)7738.51%
Cap/Depr(5y)4653.1%
Cap/Sales(3y)108.05%
Cap/Sales(5y)64.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.62%
EPS Next Y126.86%
EPS Next 2Y49.97%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue 1Y (TTM)168.71%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%18.39%
Revenue Next Year85%
Revenue Next 2Y45.1%
Revenue Next 3Y35.53%
Revenue Next 5YN/A
EBIT growth 1Y141.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year177.34%
EBIT Next 3Y51.87%
EBIT Next 5YN/A
FCF growth 1Y34.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y85.47%
OCF growth 3YN/A
OCF growth 5YN/A
XOMA ROYALTY CORPORATION / XOMA FAQ
Can you provide the ChartMill fundamental rating for XOMA ROYALTY CORPORATION?
ChartMill assigns a fundamental rating of 4 / 10 to XOMA.
Can you provide the valuation status for XOMA ROYALTY CORPORATION?
ChartMill assigns a valuation rating of 4 / 10 to XOMA ROYALTY CORPORATION (XOMA). This can be considered as Fairly Valued.
How profitable is XOMA ROYALTY CORPORATION (XOMA) stock?
XOMA ROYALTY CORPORATION (XOMA) has a profitability rating of 4 / 10.
What is the expected EPS growth for XOMA ROYALTY CORPORATION (XOMA) stock?
The Earnings per Share (EPS) of XOMA ROYALTY CORPORATION (XOMA) is expected to grow by 126.86% in the next year.